Holen Sie sich die Stockscreener-App
1.80
1.64%
-0.03
Tenax Therapeutics Inc Aktie (TENX) Neueste Nachrichten
Tenax Therapeutics (NASDAQ:TENX) Rating Lowered to Strong Sell at Wall Street Zen - marketbeat.com
Ikarian Capital (TENX) discloses 2.9% beneficial stake in Tenax Therapeutics common stock - Stock Titan
Venrock group (TENX) discloses 1.57M-share warrant-based stake in Tenax - Stock Titan
Perceptive Advisors (TENX) reports beneficial ownership of 1.7M Tenax Therapeutics shares - Stock Titan
Tenax Therapeutics (TENX) holder BVF reports 3.11M shares, big warrant overhang - Stock Titan
Vivo Opportunity discloses 9% Tenax Therapeutics (TENX) holding via stock and warrants - Stock Titan
TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX) - Business Wire
RTW Investments discloses 9.99% Tenax Therapeutics (TENX) position with 2.87M shares - Stock Titan
TENX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Tenax Therapeutics - Morningstar
Tenax Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Tenax Therapeutics (TENX) - Morningstar
Adage Capital discloses 6.81% Tenax Therapeutics (TENX) stake via stock and warrants - Stock Titan
Tenax Therapeutics Is Maintained at Buy by Canaccord Genuity - Moomoo
Tenax Therapeutics Inc (NASDAQ: TENX) Share Price, TENX Stock News, TENX Share Price & Updates - kalkine.ca
Tenax Therapeutics downgraded to Neutral after ... - pluang.com
Tenax Stock Plunges 89% After PH-HFpEF Trial Misses Main Goal, But Subgroup Data Offers Hope - finance.biggo.com
TENX Downgraded by Chardan Capital -- Price Target Lowered to $5.00 - GuruFocus
Tenax Therapeutics (NASDAQ:TENX) Rating Lowered to Neutral at Chardan Capital - marketbeat.com
TENX Maintained by Guggenheim -- Price Target Lowered to $4.00 - GuruFocus
TENX Downgraded by Evercore ISI Group -- Price Target Lowered to $5.00 - GuruFocus
Tenax Therapeutics (NASDAQ:TENX) Downgraded by Evercore to "In-Line" - marketbeat.com
A Quick Look at Today's Ratings for Tenax Therapeutics(TENX.US), With a Forecast Between $4 to $4 - Moomoo
Leerink Partners Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Announces Target Price $4 - Moomoo
Guggenheim cuts Tenax Therapeutics price target to $4 on trial miss - Investing.com South Africa
TENAX THERAPEUTICS INC : WILLIAM BLAIR CUTS TO MARKET PERFORM RATING - Bitget
Evercore ISI Downgrades Tenax Therapeutics to In Line From Outperform, Adjusts PT to $5 From $39 - marketscreener.com
Tenax Therapeutics’ stock crashes on Phase III trial failure - Yahoo Finance
We're Not Very Worried About Tenax Therapeutics' (NASDAQ:TENX) Cash Burn Rate - simplywall.st
TENAX THERAPEUTICS INC : LEERINK PARTNERS CUTS TARGET PRICE TO $4 FROM $26 - Bitget
Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF PatientsSlideshow (NASDAQ:TENX) 2026-08-11 - Seeking Alpha
Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case - marketbeat.com
Tenax Therapeutics (TENX) Stock Crashed: Here Is Why - top1markets.com
TENAX THERAPEUTICS INC : CANACCORD GENUITY CUTS TARGET PRICE TO $4 FROM $35 - Bitget
Tenax Therapeutics, Inc. (NASDAQ: TENX) Investors: Johnson Fistel Investigates Potential Securities Law Violations After Phase 3 Trial Failure; Shares Plummet Nearly 90% - lincolnjournal.com
Tenax Therapeutics, Inc. (NASDAQ: TENX) Investors: Johnson - GlobeNewswire
Tenax Therapeutics (NASDAQ:TENX) Sets New 52-Week LowHere's Why - marketbeat.com
William Blair downgrades Tenax Therapeutics stock rating on trial results By Investing.com - Investing.com UK
TENX Downgraded by William Blair -- Rating Changed to Market Per - GuruFocus
Chapel Hill drug developer's stock plunges 90% after trial setback - The Business Journals
William Blair Downgrades Tenax Therapeutics(TENX.US) to Hold Rating - Moomoo
William Blair downgrades Tenax Therapeutics stock rating on trial results - Investing.com Nigeria
Tenax Therapeutics Stock Dives as It Faces Heart Drug Study Setback - Benzinga
Tenax drug trial misses mark, shares plunge 90% - Business North Carolina
Tenax, Sionna Shares Sink After Trial Failures -- WSJ - Bitget
Tenax Therapeutics shares plunged 87.2% after the company's heart drug failed to meet the primary endpoint in a late-stage study. - Bitget
Tenax Therapeutics (TENX) Shares Collapse 89% After Phase 3 Tria - GuruFocus
Tenax Therapeutics Phase 3 LEVEL Trial Misses Primary Endpoint for TNX-103 - Yahoo Finance
Why Did TENX Stock Crash 89% Today? - Yahoo Finance
Tenax Therapeutics (TENX) Stock Plummets 87% Amid Clinical Setba - GuruFocus
Tenax Therapeutics Inc. (TENX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Tenax Therapeutics (TENX) Stock Drops 84% After Phase 3 LEVEL Trial Misses Primary Endpoint - CoinCentral
TENX Stock Whipsaws As Traders Target Volatile Setup - timothysykes.com
TENX Stock Whipsaws As Traders Eye Volatility And Cash Pile - StocksToTrade
Tenax Therapeutics (NASDAQ:TENX) Drops 85% as Phase 3 LEVEL Study Fails to Meet Main Endpoints - TechStock²
TENX Stock Whipsaws As Traders Track Volatility And Cash Runway - timothysykes.com
Why is Tenax Therapeutics stock collapsing today? By Investing.com - Investing.com Nigeria
Tenax Therapeutics (TENX) Reports Phase 3 LEVEL Trial Results, F - GuruFocus
Tenax Therapeutics Stock Plummets 84% After Phase 3 Trial Failure - StockInvest.us
Tenax Therapeutics Inc To Discuss the Topline Level Results Transcript - GuruFocus
Tenax says Phase 3 LEVEL trial of TNX-103 in PH-HFpEF misses primary endpoint on 6-minute walk distance - Bitget
Tenax Therapeutics Phase 3 LEVEL Trial Topline Results - TipRanks
Heart failure drug from Tenax Therapeutics fails in pivotal study - STAT
Top Premarket Decliners - marketscreener.com
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):